AELIX Therapeutics presents positive results from randomized placebo-controlled phase I/IIa therapeutic HIV vaccine clinical trial
• Investigational AELIX HTI vaccine leads to prolonged period without antiretroviral treatment (ART)
• Vaccine-induced immune T cell responses significantly correlate with prolonged time off ART
• Results support development of combination strategies based on HTI vaccine to control HIV – without the need for ongoing antiretroviral medication
Advent France Biotechnology participe au tour de table de Série B de 74M$ (61,5M€) d’AgomAb Therapeutics
Tollys welcomes Dr. Jean-Pierre Armand as member of its scientific advisory board
CVasThera secures €1.3 Million in first funding round
Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01
Biomunex Pharmaceuticals signs strategic license and co-development agreement with Onward Therapeutics for proprietary bispecific antibody program
Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy
• No currently marketed drugs are able to stop the progression of epilepsy, those available only help manage seizures
• More than 30% of patients do not respond adequately to those drugs carrying risks of structural damage to the brain and nervous system, comorbidities and increased mortality
• Accure Tx’s candidate ACT-03 demonstrates in animal models anti-epileptogenic activity while protecting against cognitive decline
Tollys appoints Philippe Goupit as chairman of the board